Rydex Biotechnology Fund Class A (RYBOX)

82.36
Net Asset Value
+0.26%
1 Day
+2.08%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
4.75
Sales Expenses
1.61%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances- the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives- which primarily consist of futures contracts and options on securities- futures contracts- and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

Performance

1 month+0.94% 3 years-1.17%
3 months-3.42% 5 years+12.55%
1 year+16.63% Since inception+12.33%
Data through --

Peer Comparisonvs. Health

 RYBOXCategory
Performance 5-yr return+12.55%+14.29%
Expense ratio1.61%1.29%
Risk 5 year sharpe ratio0.590.89
Net assets$259.7M$2.9B
Average market cap$12.6B$9.8B
Average P/E31.122.0
Portfolio turnover207%207%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 20 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock99.66%
Cash3.51%
International stock0.00%
Fixed income0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie6.40%
AMGN Amgen6.16%
GILD Gilead Sciences5.28%
CELG Celgene4.51%
BIIB Biogen4.28%
ILMN Illumina Inc3.36%
VRTX Vertex Pharmaceuticals Inc3.34%
REGN Regeneron Pharmaceuticals3.10%
ALXN Alexion Pharmaceuticals Inc2.84%
BMRN Biomarin Pharmaceutical Inc2.20%